ArticleCureus2025
Efficacy and Safety of Albendazole Versus Albendazole and Ivermectin in Reduction of Soil-Transmitted Helminth Infections in School-Age Children (DVERMIN): A Double-Blind, Randomized, Controlled Trial.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSoil-transmitted helminth (STH) infections are endemic in India despite considerable improvements in hygiene conditions and regular deworming. This multicentric, double-blind, randomized controlled trial (Efficacy and Safety of Albendazole Versus AlbenDazole and IVERmectin in Reduction of Soil-Transmitted HelMINth Infections in School-Age Children (DVERMIN)) was conducted to evaluate the efficacy and safety of albendazole versus albendazole + ivermectin in the treatment of STH infections and to evaluate the prevalence of stool-positivity for STH in school-going children from 12 schools of Lucknow and Kolkata.
methodsThis was a randomized controlled trial conducted from March 2022 to February 2023. The included children aged 6-15 years were administered single-dose oral suspension of albendazole (400 mg) or albendazole (400 mg) + ivermectin (3/6/12 mg based on body weight). The primary endpoint was the microbiological cure rate (proportion of infected children having egg-free stool samples post single-dose treatment) on Day 7. The secondary endpoints were egg reduction rate and clinical cure rate (proportion of children with symptom resolution) on Day 7, and the proportion of children in the regions of study conduct with stool positivity for STH at baseline. Safety was assessed based on adverse events (AEs).
resultsAmong the 1233 eligible children, stool samples from 1067 were evaluable at baseline. A total of 416 (38.99%) of these 1067 samples were egg-positive.
conclusionsOverall, both treatments were found to be effective and safe in school-age children. The rates of microbiological cure, egg reduction, and clinical cure were not significantly different between the groups; however, a clinical advantage was demonstrated in the albendazole + ivermectin group with respect to egg reduction and clinical cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.